Go Deep
Nectar Lifesciences Limited
Nectar Lifesciences Limited Score & Ratio Trend
Not enough history yet — this builds up over time as the company refreshes monthly. Check back in a few weeks.
Nectar Lifesciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 145,000.0 | 0.0 | 0.0 | 49,966,000.0 |
| Net Profit | -153,977,000.0 | -679,242,000.0 | 142,697,000.0 | -3,293,000.0 |
| EPS | -0.8 | -3.4 | 0.6 | -7.8 |
Nectar Lifesciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 16,840,860,000.0 | 15,236,700,000.0 | — |
| Net Profit | -2,928,910,000.0 | -1,136,810,000.0 | 49,950,000.0 | -241,830,000.0 | — |
| EPS | -13.4 | -5.1 | 0.2 | -1.1 | — |
Nectar Lifesciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 6,216,060,000.0 | 20,472,250,000.0 | 21,910,560,000.0 | 21,892,110,000.0 | — |
| Total Liabilities | 393,110,000.0 | 10,911,190,000.0 | 11,218,020,000.0 | 11,246,170,000.0 | — |
| Total Equity | 5,822,950,000.0 | 9,561,060,000.0 | 10,692,540,000.0 | 10,645,940,000.0 | — |
Nectar Lifesciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 20.1%Fixed assets (tangible) 16.6%Other assets 62.5%
How it's funded — Mar 2026
Other liabilities 6.3%Shareholders' equity 93.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 125.1 | 19.7 | 20.3 | 17.9 |
| Receivables | 0.0 | 345.5 | 379.2 | 279.6 |
| Inventory | 0.3 | 690.2 | 709.2 | 672.6 |
| Fixed assets (tangible) | 103.4 | 633.3 | 656.1 | 690.4 |
| Intangible assets | 1.1 | 56.5 | 52.4 | 49.3 |
| Long-term investments | 3.0 | 0.0 | 0.0 | 0.2 |
| Other assets | 388.7 | 302.0 | 374.0 | 479.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 521.9 | 495.2 | 527.4 |
| Long-term debt | 0.0 | 60.1 | 140.3 | 226.5 |
| Payables | 0.0 | 438.1 | 419.7 | 318.8 |
| Other liabilities | 39.3 | 71.0 | 66.6 | 52.0 |
| Shareholders' equity | 582.3 | 956.1 | 1,069.3 | 1,064.6 |
| Net tangible assets | 581.2 | 899.6 | 1,016.9 | 1,015.3 |
Nectar Lifesciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -4,173,520,000.0 | 1,694,380,000.0 | 2,246,860,000.0 | 1,336,510,000.0 | — |
| Investing Activities | 12,054,110,000.0 | -419,300,000.0 | -170,250,000.0 | 517,040,000.0 | — |
| Financing Activities | -6,991,480,000.0 | -1,280,920,000.0 | -2,054,350,000.0 | -1,855,830,000.0 | — |